Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis
Sung Hee Choi, … , Sanford D. Markowitz, John J. Letterio
Sung Hee Choi, … , Sanford D. Markowitz, John J. Letterio
Published May 16, 2014
Citation Information: J Clin Invest. 2014;124(6):2472-2482. https://doi.org/10.1172/JCI69672.
View: Text | PDF
Research Article Oncology

Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis

  • Text
  • PDF
Abstract

Colitis-associated colon cancer (CAC) develops as a result of inflammation-induced epithelial transformation, which occurs in response to inflammatory cytokine-dependent downregulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and subsequent suppression of prostaglandin metabolism. Agents that both enhance 15-PGDH expression and suppress cyclooxygenase-2 (COX-2) production may more effectively prevent CAC. Synthetic triterpenoids are a class of small molecules that suppress COX-2 as well as inflammatory cytokine signaling. Here, we found that administration of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-C28-methyl ester (CDDO-Me) suppresses CAC in mice. In a spontaneous, inflammation-driven intestinal neoplasia model, deletion of Smad4 specifically in T cells led to progressive production of inflammatory cytokines, including TNF-α, IFN-γ, iNOS, IL-6, IL-1β; as well as activation of STAT1 and STAT3; along with suppression of 15-PGDH expression. Oral administration of CDDO-Me to mice with SMAD4-deficient T cells increased survival and suppressed intestinal epithelial neoplasia by decreasing production of inflammatory mediators and increasing expression of 15-PGDH. Induction of 15-PGDH by CDDO-Me was dose dependent in epithelial cells and was abrogated following treatment with TGF-β signaling inhibitors in vitro. Furthermore, CDDO-Me–dependent 15-PGDH induction was not observed in Smad3–/– mice. Similarly, CDDO-Me suppressed azoxymethane plus dextran sodium sulfate–induced carcinogenesis in wild-type animals, highlighting the potential of small molecules of the triterpenoid family as effective agents for the chemoprevention of CAC in humans.

Authors

Sung Hee Choi, Byung-Gyu Kim, Janet Robinson, Steve Fink, Min Yan, Michael B. Sporn, Sanford D. Markowitz, John J. Letterio

×

Figure 6

CDDO-Me increases the expression of 15-PGDH in colon epithelial cells.

Options: View larger image (or click on image) Download as PowerPoint
CDDO-Me increases the expression of 15-PGDH in colon epithelial cells.
(...
(A) Expression of 15-PGDH protein and mRNA after treatment with CDDO-Me. FET cells were treated with various doses of CDDO-Me (0–300 nM) for 24 hours. Expression of 15-PGDH protein and mRNA was analyzed by Western blotting and RT-PCR analysis (β-actin was used as a control). Lanes were run on the same gel but were noncontiguous. The data shown are representative of 6 independent experiments. (B) Time-dependent effect of CDDO-Me (100 nM) on 15-PGDH expression. FET cells were treated with CDDO-Me (100 nM) for 6, 12, 24, 48, and 72 hours and analyzed by Western blot. The data shown are representative of 3 independent experiments. (C) CDDO-Me–induced 15-PGDH promoter luciferase activity. pGL3 and 15-PGDH promoter activity in FET cells following stimulation with CDDO-Me (300 nM) for 24 hours. The fold induction of the relative levels of 15-PGDH transcripts was compared with that of untreated pGL3 transcripts. A dual luciferase assay was performed, and data shown are averages of triplicate independent measurements of Firefly/Renilla luciferase readings normalized to untreated controls. Data represent average ± SEM (n = 4–6). (D) CDDO-Me inhibited colon epithelial cellular proliferation in a dose-dependent manner. 5 × 103 FET cells were cultured with CDDO-Me (0–300 nM) in 96-well plates with treatment, and proliferation was assessed by incorporation of 3H-thymidine.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts